Recipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango

Allogeneic hematopoietic stem cell transplantation (alloHSCT) produces –similar to the long-established graft-versus-leukemia effect– graft-versus-solid-tumor effects. Clinical trials reported response rates of up to 53%, occurring mostly but not invariably in association with full donor chimerism and/or graft-versus-host disease. Although donor-derived T cells are considered the principal effectors of anti-tumor immunity after alloHSCT or donor leukocyte infusion (DLI), growing evidence indicate that recipient-derived immune cells may also contribute.

Source: Blood Reviews - April 12, 2018 Category: Hematology Authors: Isabelle Dierckx de Casterl é, An D. Billiau, Ben Sprangers Tags: Review Source Type: research